Whalesbook
Kyunki bade drug patents expire ho rahe hain, companiyan apne brands ko defend karne mein lagi hain. Bombay High Court ne toh Sun Pharma ke favor mein faisla sunate hue 'PANTOZED-40' ki marketing rok di kyunki woh Sun Pharma ke 'Pantocid' se milta-julta tha aur confusion create kar sakta tha. Aur ek bade case mein, Dr. Reddy's Laboratories ko apne semaglutide generic 'Olymviq' ko sell karne se roka gaya kyunki woh Novo Nordisk ke blockbuster drug 'Ozempic' se bahut similar tha. Ab Dr. Reddy's ko 30 din ke andar ek naya naam soch ke sell karna hoga, shayad 'Olymra'. Yahi haal Intas Pharmaceuticals ka hai, jinki oncology brand 'Bevtas' ko bhi Sun Pharma ke 'Bevetex' se milta-julta hone ki wajah se restrictions ka saamna karna pada.
Ab tum soch rahe hoge ki naam itna important kyun hai? Bhai, drug industry mein brand name sirf marketing ke liye nahi hai, yeh patient safety aur company ke success ke liye sabse zaroori hai. Experts bolte hain ki agar names milte-julte honge toh medication errors ka bahut bada risk hai, khaas kar jab prescriptions hath se likhi ho ya verbally di gayi ho. Indian courts bhi public health ko dhyan mein rakhte hue aise confusing trademarks ke khilaaf sakhti kar rahe hain. Ek trusted brand patients aur doctors dono ka bharosa jeetta hai, jis se prescribing decisions change hote hain aur patent khatam hone ke baad bhi loyalty bani rehti hai. Yeh brand reputation ek jackpot hai, jo higher prices ko support karta hai aur competitive fields mein edge deta hai.
Aur yeh sab jhagde kyun badh rahe hain? Kyunki bahut saare big drug patents ab expire ho rahe hain, jisko 'patent cliff' bhi bolte hain. Isse saste generic versions aate hain aur medicines zyada accessible hoti hain, par yeh brand disputes ko bhi trigger karta hai kyunki original manufacturers apna market share bachane mein lag jaate hain. India ke drug naming rules ko thoda weak mana jaata hai, kyunki oversight kam hai aur central database bhi nahi hai. Companies ab khud hi promise karti hain ki unke naam confusion nahi karenge, par yeh self-certified hota hai aur central registry nahi hone se same naam aasani se aa jaate hain, jo dangerous mistakes ko lead karta hai aur public health ke liye risk banata hai.
Brand name ke confusion mein bahut bada risk hai. Lambi aur mehengi lawsuits companiyon ka paisa kha jaati hain. Brand disputes company ki reputation ko bhi damage kar sakte hain, chahe koi bhi jeete. Par sabse bada danger toh patient safety ka hai. Similar drug names ki wajah se critical medication errors ho sakte hain, jismein fatal outcomes bhi ho sakte hain. US mein FDA jaise global regulators drug names ko carefully review karte hain, par India ka system abhi thoda less stringent hai. Brand protection zaroori hai, par innovation aur public ko affordable medicines dene ke beech balance banana ek challenge hai.
Aage kya hoga? Companiyon ke beech competition badh rahi hai, toh yeh brand protection ka trend continue hone wala hai. Patent expiry ke baad, jab generics jaldi aate hain aur prices kam hote hain, tab strong brand strategy bahut zaroori ho jaati hai. Regulators bhi patient safety sudharne aur errors kam karne ke liye naming rules ko aur strict karne ka soch rahe hain. Companiyon ko ab aur zyada trademark checks, global protection plans aur continuous monitoring mein invest karna padega taaki woh apne brand assets ko secure kar saken aur market mein apni jagah bana sakein.